Balyasny Asset Management
BPMC

Balyasny Asset Management’s Blueprint Medicines BPMC Stock Holding History

Balyasny Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,000
Closed -$2.77M – 2764
2024
Q3 		$2.77M Buy
+30,000
New +$2.98M ﹤0.01% 1537

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Balyasny Asset Management's BPMC Position: Q3 2025 in Review

Balyasny Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 505,957 shares — an estimated $64.9M sold.

Balyasny Asset Management first reported a position in BPMC in Q3 2017 and held it in 15 quarters. The position peaked at $64.9M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Balyasny Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 505,957 Blueprint Medicines shares in Q3 2025, an estimated $64.9M.
  • Balyasny Asset Management first reported a position in Blueprint Medicines in Q3 2017 and held it in 15 quarters.
  • Balyasny Asset Management's Blueprint Medicines position peaked at $64.9M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Balyasny Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.